血小板衍生生长因子受体α：肝细胞癌治疗的新靶点？

PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?

作者信息

Oseini Abdul M, Roberts Lewis R

机构信息

Miles and Shirley Fiterman Center for Digestive Diseases College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

出版信息

Expert Opin Ther Targets. 2009 Apr;13(4):443-54. doi: 10.1517/14728220902719233.

DOI:10.1517/14728220902719233

PMID:19335066

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) develops most often in a background of chronic inflammatory liver injury from viral infection or alcohol use. Most HCCs are diagnosed at a stage at which surgical resection is not feasible. Even in patients receiving surgery rates of recurrence and metastasis remain high. There are few effective HCC therapies and hence a need for novel, rational approaches to treatment. Platelet derived growth factor receptor-alpha (PDGFR-alpha) is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of HCC.

OBJECTIVE

To examine PDGFR-alpha as a target for therapy of HCC and explore opportunities and strategies for PDGFR-alpha inhibition.

METHODS

A review of relevant literature.

RESULTS/CONCLUSIONS: Targeted inhibition of PDGFR-alpha is a rational strategy for prevention and therapy of HCC.

摘要

背景

肝细胞癌（HCC）最常发生于病毒感染或酒精使用所致的慢性炎症性肝损伤背景下。大多数HCC在无法进行手术切除的阶段被诊断出来。即使在接受手术的患者中，复发和转移率仍然很高。有效的HCC治疗方法很少，因此需要新颖、合理的治疗方法。血小板衍生生长因子受体-α（PDGFR-α）参与肿瘤血管生成和肿瘤微环境的维持，并与HCC的发生发展和转移有关。